

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 26, 2010

TECHNE CORPORATION
(Exact Name of Registrant as Specified in Charter)

Minnesota 0-17272 41-1427402
(State or Other Jurisdiction (Commission I.R.S. Employer
of Incorporation) File Number) Identification No.)

614 Mckinley Place NE
Minneapolis, MN 55413
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (612) 379-8854

Not Applicable
(Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- // Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- // Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- // Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- // Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

Effective May 26, 2010, Dr. Roeland Nusse was elected to the Board of Directors of Techne Corporation (the "Company") and to the Nominations and Governance Committee of the Board. In connection with his service on the Company's Board and Committee, Dr. Nusse will receive annual cash compensation and stock options pursuant to the Company's director compensation policy.

Dr. Nusse was not named as director pursuant to any arrangement or understanding with any third person. There is not currently, nor has there been in the past, any material transactions with the Company or any of its subsidiaries or affiliates in which Dr. Nusse has or had a direct or an indirect material interest.

On May 26, 2010, the Company issued a press release announcing the election of Dr. Nusse to the Company's Board of Directors. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release dated May 26, 2010.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 26, 2010

TECHNE CORPORATION

By: /s/ Thomas E. Oland

Name: Thomas E. Oland
Title: President and Chief
Executive Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Press release of Techne Corporation dated May 26, 2010.

TECHNE CORPORATION ANNOUNCES THAT DR. ROELAND NUSSE
HAS ACCEPTED A SEAT ON ITS BOARD OF DIRECTORS

Minneapolis/May 26, 2010/--Techne Corporation (NASDAQ: TECH) today announced that Roeland Nusse, Ph.D. has accepted a position on the Techne Corporation Board of Directors and will also serve as a member of Techne's Nominations and Governance Committee. Dr. Nusse's initial term will begin immediately and run through October 28, 2010. Techne Corporation's shareholders reelect all Directors on an annual basis.

Dr. Nusse has been a professor or associate professor in the Department of Developmental Biology at Stanford University and an investigator at the Howard Hughes Medical Institute since 1990. He has also been the chair of the Department of Developmental Biology at Stanford since 2007. His studies involve the activity of proteins that determine cell fate during embryogenesis. His lab has also used purified proteins to manipulate the behavior of stem cells in culture, in particular neural stem cells.

Dr. Nusse was previously at the Netherlands Cancer Institute (Amsterdam, The Netherlands) as a staff scientist and ultimately head of the Department of Molecular Biology. Dr. Nusse earned a bachelor's degree in biology in 1975 from the University of Amsterdam and a doctorate in molecular biology from the Netherlands Cancer Institute in 1980. He did his postdoctoral fellowship at the University of California, San Francisco.

Dr. Nusse was elected to the prestigious National Academy of Sciences, a private organization of scientists and engineers dedicated to the furtherance of science and its use for the general welfare, at the Academy's 147th annual meeting in April 2010. Dr. Nusse was previously named a member of the European Molecular Biology Organization in 1988, a member of the Royal Dutch Academy of Sciences in 1997 and a member of the American Academy of Arts and Sciences in 2001.

Mr. Thomas E. Oland, Techne Corporation's Chairman and CEO, said "I am extremely pleased that Dr. Nusse has accepted a position on our Board of Directors. Dr. Nusse is an esteemed scientist and his background and experience will be invaluable during the Board's strategic discussions. He will also serve as another strong mentor for the Company's senior scientific staff. We are very fortunate to have a person of his caliber on our Board. I am very confident that he will make a significant contribution to our future success."

* * * * *

Techne Corporation has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of biological products. R&D Systems has two subsidiaries, BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China. BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. R&D China and R&D Europe distribute biotechnology products.

Contact: Greg Melsen, Chief Financial Officer
Kathy Backes, Controller
(612) 379-8854